Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis

Sponsor
American University of Beirut Medical Center
Study ID
NCT02706704
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Non-Infectious Uveitis
  • Uveitis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The objective of this study is to compare and evaluate the efficacy of subcutaneous (40mg) adalimumab biweekly injections to intravitreal adalimumab (1.5 mg/ 0.03 mL) administration, given at zero, 2 weeks then every four weeks, in subjects with active non-infectious intermediate-, posterior-, or pan-uveitis.

Key Dates

Start date
Feb 29, 2016
Status verified
Feb 2025
Primary completion
Dec 31, 2025
Completion
Feb 28, 2026

Study Design

Enrollment
32 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Intravitreal
    Intravitreal injection of 1.5mg/0.03ml adalimumab given at zero, 2 weeks, and then every 4 weeks.
  • Active Comparator: Systemic
    Subcutaneous injection of 40 mg adalimumab (Humira) given every 2 weeks.

Primary Outcome Measure

Vitreous Haze [ Time Frame: 26 Weeks ]

Central Contacts

Related Studies